502 - Ralinepag, an Oral, Selective, Prostacyclin (IP) Receptor Agonist Consistently Improved Mortality Risk Scores Derived From PAH Registries Across Three Regions: Phase 2 Study Analysis - ISHLT 38th Annual Meeting and Scientific Sessions

502 - Ralinepag, an Oral, Selective, Prostacyclin (IP) Receptor Agonist Consistently Improved Mortality Risk Scores Derived From PAH Registries Across Three Regions: Phase 2 Study Analysis

Oral PH - Therapeutics and Pharmacology

502 - Ralinepag, an Oral, Selective, Prostacyclin (IP) Receptor Agonist Consistently Improved Mortality Risk Scores Derived From PAH Registries Across Three Regions: Phase 2 Study Analysis

Presentation Number

502

Presenter

R. Benza, Pittsburgh, PA, United States of America

Co-Authors

Previous Eposter

453 - Leptin Modifies the Impact of BMI on Heart Failure Progression: The Obesity Paradox Unraveling

Next Eposters

358 - Ex-vivo Lung Perfusion - 10 Year Follow-up of the First Performed Double LTX With Marginal Donor Lungs Evaluated Using EVLP

367 - OPUS Registry: Switching to Macitentan From Other Endothelin Receptor Antagonists (ERAs)

322 - Bloodstream Infections in Left Ventricular Assist Device Recipients Awaiting Transplantation

178 - By Molecular Analysis, Many ISHLT Histologic Rejection Diagnoses Are Associated With Molecular Injury, Not Molecular Rejection

446 - Sarcopenia of the Psoas Muscles Predicts Survival Following Lung Transplantation

500 - Stroke Volume Response to Exercise is Dependent on Disease Severity in Pulmonary Arterial Hypertension

297 - Is Cold Storage Possible in DCD Heart Transplantation? A Pre-Clinical Study

41 - Pulmonary Endarterectomy: Relationship Between Total Reopened Branches and Outcomes

136 - Worse Survival After Heart Transplantation in Children With Heterotaxy Syndrome

498 - Non-invasive Right Ventricle-pulmonary Artery Coupling Predicts Events in Pulmonary Arterial Hypertension and in Left Heart Disease